Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2016 Nov-Dec;10(11-12Suppl6):S224-S226.
doi: 10.5489/cuaj.4281.

Bladder cancer, ESMO 2016

Alan So  1
Affiliations
Review

Bladder cancer, ESMO 2016

Alan So. Can Urol Assoc J. 2016 Nov-Dec.
No abstract available

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Objective response in the CHECKMATE-275 study with nivolumab, overall and by PD-L1 expression.
Fig. 2
Fig. 2
Objective response in the KEYNOTE-052 study with pembrolizumab, overall and by PD-L1 expression.
See this image and copyright information in PMC

References

    1. Galsky MD, Retz M, Siefker-Radtke A, et al. Efficacy and safety of nivolumab monotherapy in patients with metastatic urothelial cancer (mUC) who have received prior treatment: Results from the phase 2 CHECKMATE-275 Study. Presented at ESMO 2016; Presentation #LBA31_PR.
    1. Rosenberg J, Bono P, Kim J, et al. Nivolumab monotherapy in metastatic urothelial carcinoma: Updated efficacy by subgroups and safety results for the CHECKMATE-032 study. Presented at ESMO 2016; Poster #784P.
    1. Balar AV, Bellmunt J, O’Donnell PH, et al. First-line pembrolizumab in cisplatin-ineligible unresectable or metastatic urothelial cancer: Interim results for KEYNOTE-52. Presented at ESMO 2016; Presentation #LBA32_PR.
    1. Bellmunt J, Balar AV, Galsky MD, et al. IMvigor210: Updated analyses of first-line atezolizumab in cisplatin-ineligible locally advanced/metastatic urothelial carcinoma. Presented at ESMO 2016; Poster #782PD. - PubMed
    1. Loriot Y, Rosenberg JE, Powles T, et al. Atezolizumab in platinum-treated locally advanced or metastatic urothelial carcinoma (mUC): Updated OS, safety and biomarkers from the phase 2 IMvigor210 study. Presented at ESMO 2016; Poster #783P.

LinkOut - more resources